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Met is a receptor tyrosine kinase for hepatocyte
growth factor. Met mutations have been considered
as a major cause of primary resistance to Met tyro-
sine kinase inhibitors (TKIs). Mutated Met enhances
its endosomal signaling, which includes internaliza-
tion, signaling within endosomes, recycling to mem-
brane, and sorting for degradation. These sequential
events lead to a plausible mechanism for resistance.
()-Antofine, a phenanthroindolizidine alkaloid, has
exhibited potent antitumor activity but the precise
underlying mechanism has been poorly understood.
We found that ()-antofine effectively inhibited the
proliferation of Met-mutated Caki-1 cells, which
were resistant to well-known Met TKIs. ()-Antofine
negatively regulated Met endosomal signaling and
consequently inhibited the nuclear translocation of
STAT3 both in vitro and in vivo. These findings
emphasize the potential of Met endosomal signaling
as a novel target for Met TKI-resistant cancers and
()-antofine as a novel lead compound associated
with the suppression of Met endosomal signaling.
INTRODUCTION
Met receptor tyrosine kinase (RTK) has a high affinity for its
endogenous ligand, hepatocyte growth factor (HGF)/scatter fac-
tor (SF). In ligand-activatedMet, the tyrosine residues Y1234 and
Y1235 in the kinase domain are phosphorylated, which leads to
autophosphorylation of the C-terminal multisubstrate docking
site, Y1349 and Y1356, of Met. Various cytoplasmic effector pro-
teins, including Ras, PLC-g, Shc, SHP2, and PI3K, are recruited
to the docking site, and subsequently, downstream signaling
cascades are activated. Signaling via ligand-activated Met has
been shown to affect a wide range of biological activities,
including cellular proliferation, scattering, invasion, morphogen-
esis, and angiogenesis (Birchmeier et al., 2003; Can˜adas et al.,
2010; Gherardi et al., 2012; Stella et al., 2010).
Because the disruption of Met function has been strongly
correlated with the pathogenesis of numerous human tumors,
Met is considered a highly attractive target in cancer therapy.
Approximately 20 different classes of small-molecule Met tyro-504 Chemistry & Biology 22, 504–515, April 23, 2015 ª2015 Elseviersine kinase inhibitors (TKIs) have been developed and some of
them are currently in clinical trials (Eder et al., 2009; Peters and
Adjei, 2012; Sattler et al., 2011). Indeed, the selective and nonse-
lective Met TKIs exhibit potent antitumor activities against Met-
driven tumors. However, recent studies suggest that primary
resistance to TKIs has emerged in tumors harboring certain
Met-activating mutations. In fact, the L1213V and Y1248H Met
mutants are resistant to SU11274, and the D1246N Met mutant
is resistant to PHA665752 (Berthou et al., 2004; Joffre et al.,
2011; Zimmer et al., 2010). In addition, recent studies have
revealed that mutations with amino acid substitutions in the
Met kinase domain are correlated with resistance to selective
Met inhibitors (Tiedt et al., 2011). Therefore, novel therapeutic
approaches are required for Met-mutated and Met TKI-resistant
cancers.
In general, it has been believed that receptors signal only when
they are in the plasma membrane and that the signal is dimin-
ished by their internalization and subsequent degradation. How-
ever, like a few RTKs, including epidermal growth factor receptor
(EGFR), and platelet-derived growth factor receptor (PDGFR),
Met is able to transduce signals from endosomes, even after
endocytosis (Kermorgant and Parker, 2008; Kermorgant et al.,
2004). After the ligand HGF binds to the Met receptor, Met
undergoes clathrin- and dynamin-mediated endocytosis. HGF-
bound Met is recruited to early endosome antigen 1 (EEA1)-pos-
itive peripheral endosomes, which are early/sorting endosomes.
Subsequently, Met is trafficked to late endosome/multivesicular
bodies (MVBs), which are positive for Lamp1 and Rab7. Prior to
degradation, Met signals are transduced from endosomes
(Joffre et al., 2013; Lefebvre et al., 2012). This endosomal
signaling, including Met internalization, signaling within early en-
dosomes, recycling to the plasmamembrane and sorting to spe-
cific endosomes for degradation, is considered an important part
of the optimal activation of Met downstream targets.
It has been reported that the endocytosis of active Met is
required to sustain the phosphorylation of signal transducer
and activator of transcription 3 (STAT3) and extracellular-signal
regulated kinase 1/2 (ERK1/2). Moreover, after trafficking to
the perinuclear compartment of the active endosome, Met stim-
ulates the phosphorylation of tyrosine 705 of STAT3, which is
necessary for the translocation of STAT3 into the nucleus (Ker-
morgant and Parker, 2008). Recently, it has also been reported
that mutated Met with a D1246N or an M1268N in its kinase
domain not only displays constitutive tyrosine phosphorylation
but also exhibits increased endocytosis and recycling activity,
leading to a decreased level of degradation. Furthermore,Ltd All rights reserved
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Figure 1. The Anti-proliferative Activity of
(–)-Antofine Depends on Met Expression
(A) The chemical structure of ()-antofine.
(B) A phospho-RTK array of Caki-1 cells. Cells
were treated with or without the indicated con-
centrations of ()-antofine for 24 hr. The blots
reflect the phosphorylation status of 42 RTKs. The
position of phospho-Met spots are indicated. Each
RTK is spotted in duplicate, and the pairs of dots in
each corner of the array are positive or negative
controls.
(C) Characterization of cell lines for Met expression
at both mRNA (left) and protein (right) levels.
(D) Characterization of cell lines for HGF expres-
sion at the mRNA level.
(E) The antiproliferative activity of ()-antofine.
(F) The antiproliferative activities of well-known
Met TKIs, including PHA665752, cabozantinib,
and BMS777607. Cell viability was determined
using the sulforhodamine B assay. The indicated
cells were treated with various concentrations of
each compound for 72 hr. Data are represented as
means ± SEM.when the endocytosis of Met was blocked, tumorigenesis in vivo
was also inhibited regardless of its activation. These results sug-
gest that endosomal signaling of Met plays an important role in
its oncogenic property in Met-activated mutants (Joffre et al.,
2011). Therefore, the interruption of endosomal signaling might
be a novel therapeutic strategy for treating Met-driven cancers.
Phenanthroindolizidine alkaloids are bioactive pentacyclic
natural products isolated from Cynanchum, Pergularia, Tylo-
phora, and other genera of the Asclepiadaceae family. They
show interesting biological activities, including antimicrobial,
antiviral, anti-inflammatory activity, and potent antiproliferative
activity against various cancer cell lines (Gao et al., 2004; Gellert,
1982; Stærk et al., 2002). Antitumor screening of these com-
pounds performed by the National Cancer Institute (NCI) re-
vealed a highly potent inhibitory effect on the proliferation (con-
centration for 50%of maximal inhibition of cell proliferation [GI50]
108 M) of all 60 cell lines tested. In addition, based on
COMPARE analysis, the mode of action of this class of com-
pounds is different from other known anticancer agents (Paull
et al., 1995). ()-Antofine (Figure 1A) is a representative phenan-
throindolizidine alkaloid, and it has been reported to be a potent
and promising anticancer compound by our group and others
(Lee et al., 2003; Min et al., 2010; Stærk et al., 2002). Several bio-
logical functions of ()-antofine have previously been elucidated,
including the suppression of DNA and protein synthesis, induc-Chemistry & Biology 22, 504–515, April 23, 2015tion of apoptosis, and inhibition of nuclear
factor-kB (NF-kB) activation, but specific
targets remain unknown (Min et al., 2010;
Shiah et al., 2006). These reports implied
that ()-antofine has a broad spectrum of
cellular effects, which prompted us to
investigate more relevant targets for its
biological activity.
In the present study, we suggest that
Met RTK is a potential target for the anti-
proliferative activity of ()-antofine in
various cancer cell lines. To elucidate themolecular mechanisms
involved in Met signaling, Caki-1 was used as a model cell line.
Caki-1 is a highly metastatic and resistant renal cell carcinoma
(RCC) line, which is resistant to conventional chemotherapeutics
(Fujimoto et al., 2005). However, ()-antofine exhibited a potent
antiproliferative activity against Caki-1 cells, unlike other chemo-
therapeutics. Therefore, we identified the negative regulation of
Met endosomal signaling as a plausible mechanism of action
of ()-antofine using Caki-1 cells in vitro and in vivo.
RESULTS
The Antiproliferative Activity of (–)-Antofine Correlates
with Met Expression
To investigate the molecular targets of the antiproliferative activ-
ity of ()-antofine in cancer cells, we primarily employed phos-
pho-RTK arrays. As shown in Figure 1B, Caki-1 cells were found
to express a high level of phosphorylated Met (phospho-Met),
but the treatment with ()-antofine (25 nM) for 24 hr markedly
suppressed the expression of phospho-Met. Based on this infor-
mation, we hypothesized that the Met RTK might be a plausible
target of ()-antofine associated with the growth inhibition of
cancer cells. We then evaluated six different cancer cell lines
to elucidate the relationship between Met expression and the
antiproliferative activity of ()-antofine. Interestingly, we foundª2015 Elsevier Ltd All rights reserved 505
that cell lines with high expression levels of Met mRNA and pro-
tein (Caki-1 and A549) or the Met ligand HGF mRNA (U87MG)
were sensitive to the growth-inhibitory activity of ()-antofine
(Figures 1C–1E). In addition, Caki-1 expressed high levels of
phospho-Met (Y1234/1235), implying that in Caki-1 cells, Met
is highly activated (Figure 1C).
Generally, Met-mutated variants tend to be resistant to the
known Met TKIs (Berthou et al., 2004; Joffre et al., 2011; Tiedt
et al., 2011; Zimmer et al., 2010). Caki-1 has the V1238I
missense mutation in the hinge region of the kinase domain
and exhibits a constitutively high kinase activity (Forbes et al.,
2006). As shown in Figure 1F, Caki-1 was also found to be
resistant to the well-known Met TKIs cabozantinib and
BMS777607. In the other cell lines, the antiproliferative activ-
ities of cabozantinib and BMS777607 are dependent on the
expression levels of Met.
(–)-Antofine Induces c-cbl-Dependent Proteasomal
Degradation of Met
In comparison with the knownMet TKIs, which do not inhibit Met
mutants, ()-antofine potently inhibits the growth of cancer cells,
even whenMet is mutated (in Caki-1 cells). To confirm this differ-
ence in the antiproliferative activity of ()-antofine and other Met
TKIs, the expression of the Met and phospho-Met (Y1234/1235)
proteins was examined usingWestern blot analysis in Caki-1 and
U87MG cells. Caki-1 cells were used to evaluate the ligand-inde-
pendent, mutated activity of Met and U87MG cells were used to
assess the ligand-dependent activity. As shown in Figure 2A,
treatment with PHA665752, cabozantinib, BMS777607, or
()-antofine for 24 hr suppressed the expression of phospho-
Met in both cell lines. The U87MG cells were more sensitive to
the suppression of phospho-Met expression than Caki-1 cells.
Concentrations of 1 nM of ()-antofine or PHA665752 and
100 nM of cabozantinib or BMS777607 were sufficient to
completely suppress phospho-Met in U87MG cells. In Caki-1
cells, however, cabozantinib and BMS777607 had little effect
on the expression of phospho-Met, even at a concentration of
1,000 nM. PHA665752 markedly suppressed phospho-Met at
10 nM and completely suppressed it at 100 nM in Caki-1 cells.
In contrast, ()-antofine completely suppressed phospho-Met
at 1 nM in both Caki-1 and U87MG cells. In addition, ()-antofine
(25 nM) almost entirely suppressed the expression of phospho-
Met with 30 min of treatment (Figure 2B).
To examine whether ()-antofine was able to suppress the ki-
nase activity of Met, the kinase assay was carried out using Met
kinase enzyme kits. Unlike cabozantinib, which inhibited the Met
kinase activity as a function of dose (the IC50 value was 0.81 nM),
()-antofine did not effectively inhibit the kinase activity (Fig-
ure 2C). These data indicated that ()-antofine suppressed the
expression of phospho-Met by a different mechanism than other
Met TKIs.
To confirm that ()-antofine regulated Met expression by a
mechanism of action different from that of other TKIs, we tested
the ability of ()-antofine to enhance the proteolytic degradation
of Met. When Met protein levels were monitored for up to 6 hr af-
ter pretreatment with cycloheximide, the results indicated that
Met was more quickly degraded in ()-antofine-treated cells
than in control cells (Figure 2D). Next, we examined the effects
of MG132 (a 26S proteasome inhibitor) or chloroquine (a lyso-506 Chemistry & Biology 22, 504–515, April 23, 2015 ª2015 Elseviersomal inhibitor) on the degradation of Met in the presence of
()-antofine to determine the degradation pathway. As shown
in Figure 2E, cotreatment with MG132 abrogated the suppres-
sion of Met expression by ()-antofine but the treatment with
chloroquine did not affect the degradation of Met. Immunopre-
cipitation assays conducted with total cell lysates showed that
()-antofine with MG132 pretreatment significantly increased
ubiquitinated Met (Figure 2F). These data suggested that
()-antofine promoted Met ubiquitination and subsequent
degradation by the proteasome.
After ligand stimulation, phospho-Met recruits the E3 ubiquitin
ligase casitas B-lineage lymphoma (c-cbl), which promotes
ubiquitination of the receptor. c-cbl is recruited directly by asso-
ciation with the phosphorylated Y1003 of Met (Gherardi et al.,
2012). We next determined whether enhancement of ubiquitina-
tion of Met by ()-antofine is associated with the interaction be-
tween c-cbl and Met using immunoprecipitation assays. As
shown in Figure 3A, treatment with ()-antofine (25 nM) for 4 hr
did not affect the level of c-cbl in the total cell lysate or in the
eluent. However, when cells were pretreated with MG132, the
binding of Met and c-cbl dramatically increased. These results
indicate that Met associates with c-cbl prior to proteasomal
degradation. In addition, the levels of phospho-Met (both
Y1234/1235 and Y1003) in the eluent were highly elevated
compared with the levels in the total cell lysate, suggesting
that the phosphorylated form of Met is predominant in the bind-
ing with c-cbl.
To further confirm that c-cbl is crucial to Met degradation,
small interfering (siRNA) experiments were conducted. The
selected stealth siRNA for c-cbl effectively suppressed the
expression of c-cbl mRNA and protein levels (Figure 3B). Based
on the RNAi efficiency, the Caki-1 cells were transfected with
either a negative control or the CBL siRNA and then treated
with ()-antofine for 24 hr. The increased Met degradation by
()-antofine was abolished by CBL siRNA, implying that
()-antofine enhanced the proteasomal degradation of Met in a
c-cbl-dependent manner (Figure 3B).
We confirmed these results using immunocytochemical anal-
ysis and confocal microscopy (Figure 3C). Generally, wild-type
Met is expressed in the plasma membrane in unstimulated cells.
However, Met-mutant Caki-1 cells were found to express high
levels of Met proteins in all cell compartments. The treatment
with ()-antofine diminished and localized the Met proteins in
the cytosolic compartments in a time-dependent manner. Simul-
taneously, Met was found to be colocalized with ubiquitin and
c-cbl in a time-dependent manner.
(–)-Antofine Attenuates Met Endosomal Signaling by
Inhibiting Endocytosis and Recycling as well as
Enhancing Degradation
We next determined whether ()-antofine affects Met endoso-
mal signaling by regulating Met endocytosis and recycling. First,
the degradation levels of cell surface Met were analyzed using a
biotinylation degradation assay (see the Experimental Proce-
dures). After treatment with ()-antofine (25 nM) for 4 hr, the total
biotinylated Met proteins were detected in cell lysates.
Compared with the vehicle-treated control cells, cells treated
with ()-antofine showed enhanced degradation of cell surface
Met proteins (Figure 4A).Ltd All rights reserved
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Figure 2. (–)-Antofine Induces Proteasomal Met Degradation
(A) Western blot analysis of Caki-1 and U87MG cells. Cells were treated with or without the indicated concentrations of ()-antofine, PHA665752, cabozantinib or
BMS777607 for 24 hr.
(B) Western blot analysis of Caki-1 cells. Cells were treated with 25 nM ()-antofine for the indicated times.
(C) Met kinase enzyme assay. Reactions were carried out using 30 ng/well Met, 200 mg/ml poly (Glu4Tyr1) as a substrate, and 50 mMATP for 30 min. RLU, relative
luciferase units. Data are represented as means ± SD.
(D) Western blot analysis of Caki-1 cells. Cells were treated with 25 mM cycloheximide with or without 25 nM ()-antofine for the indicated times.
(E)Western blot analysis of Caki-1 cells. Cells were treated with or without 25 nM ()-antofine for 4 hr after pretreatment with 10 mMMG132 or chloroquine for 1 hr.
(F) Immunoprecipitation of Caki-1 cells. Cells were treated with or without 25 nM ()-antofine for 4 hr after pretreatment with 10 mMMG132 or not. The total cell
lysates were immunoprecipitated with Met antibody and immunoblotted with Ub antibody.Second, the internalization and subsequent endosomal recy-
cling of cell surface biotinylated Met were measured using a bio-
tinylation internalization and recycling assay (biotin cleavage atChemistry & Biology 22,the cell surface allowing determination of intracellular bio-
tinylated Met: see the Experimental Procedures). For this assay,
two time 0 controls were required. To measure the total Met at504–515, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 507
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Figure 3. Proteasomal Met Degradation Induced by (–)-Antofine Is c-cbl Dependent
(A) Immunoprecipitation of Caki-1 cells. Cells were treated with or without 25 nM ()-antofine for 4 hr after pretreatment with 10 mMMG132. The total cell lysates
were immunoprecipitated with Met antibody and immunoblotted with the indicated antibodies.
(B) RNAi experiments with Caki-1 cells. Cells were transfected with negative control siRNA orCBL siRNA for 24 hr and treated with 25 nM ()-antofine for a further
24 hr. The cell lysates were immunoblotted with the indicated antibodies (lower panel). The levels of CBL mRNA (left) and c-cbl protein (right) expression are
indicated in the upper panel. Data are represented as means ± SEM.
(C) Confocal microscopic analysis of Caki-1 cells. Cells were treated with 25 nM ()-antofine for the indicated times and stained with Met, Ub, c-cbl antibodies,
and DAPI. Scale bars represent 40 mm.
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Figure 4. (–)-Antofine Regulates Met Degradation, Endocytosis and Recycling
(A) Biotinylation degradation assay of Caki-1 cells. Cells were surface biotinylated and incubated at 37C for 4 hr with or without 25 nM ()-antofine. After in-
cubation, the cells were lysed (total). A streptavidin pulldown was conducted with the total cell lysate and the remaining biotinylatedMet (pulldown) was analyzed
using Western blotting with Met antibody.
(B) Biotinylation internalization/recycling assay of Caki-1 cells. In the Caki-1 cells, the levels of surface biotinylated Met internalized (1 hr) and recycled (1 hr) were
measured with or without treatment with 25 nM ()-antofine. In this assay, two time 0 controls were carried out. The total Met at the surface was measured (total
surface Met in the time 0 controls) and the efficiency of the surface biotin removal was also verified (reduction of control [CTL] in the time 0 controls).
(C) Confocal microscopy analysis of Caki-1 cells. Cells were treated with 25 nM ()-antofine for the indicated times and stained with Met, EEA1, Lamp1 anti-
bodies, and DAPI. Scale bars represent 20 mm.the surface, biotinylated cells at 4C were lysed without biotin
reduction. To verify the efficiency of the surface biotin cleavage,
the biotin reduction and MesNa quenching steps were carried
out on cells that remained on ice, after which the cells were lysed
(Figure 4B, left panel). Treatment with ()-antofine (25 nM) for
1 hr inhibited the internalization of Met protein (Figure 4B, middle
panel). Reincubation for an additional 1 hr led to recycling of
internalized endosomal Met protein. Treatment with ()-antofine
(25 nM), however, resulted in much higher levels of internalized
Met protein in the cytosol, indicating that ()-antofine might
inhibit Met recycling to the peripheral membranes (Figure 4B,
right panel).
To identify the subcellular compartments in which Met traf-
fics, triple staining of Met with endosomal markers, including
EEA1 and Lamp1, was carried out after ()-antofine treatment
for up to 8 hr. Colocalization of the markers was analyzed usingChemistry & Biology 22,confocal microscopy (Figure 4C). Met colocalized with EEA1 in
control cells, whereas little colocalization was detected after
()-antofine treatment for 8 hr. Moreover, colocalization of
Met with Lamp1 after ()-antofine treatment was time
dependent.
Under basal conditions, Met localized on early endosomes
(Figure 4C) and recycled back to the plasma membrane
(Figure 4B) in Caki-1 cells, which have a V1238I mutation in
Met. This indicates that the mutated Met accumulates on en-
dosomal compartments through constitutive shuttling be-
tween the plasma membrane and the endosomes and thus
impairs the degradation of Met. We found that ()-antofine
not only increased the degradation of the mutated Met but
also inhibited the rates of endocytosis and recycling, sug-
gesting that ()-antofine attenuated the endosomal signaling
of Met.504–515, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 509
(–)-Antofine Affects STAT3 Activity by Regulating Met
Endosomal Signaling
Activated Met can stimulate multiple signal transduction path-
ways. Therefore, we explored whether ()-antofine affects the
downstream signaling molecules of Met. Western blot analysis
revealed that the protein levels of Grb2 and RAC1 were downre-
gulated by ()-antofine. In addition, phosphorylated Src,
ERK1/2, and STAT3 protein levels were downregulated by
()-antofine in a dose-dependent manner (Figure 5A). These
findings suggest that ()-antofine suppresses the downstream
targets of Met signaling.
It was reported that direct binding of STAT3 to Met is required
for STAT3 phosphorylation and translocation into the nucleus
(Boccaccio et al., 1998). To confirm that the effect of ()-antofine
on STAT3 phosphorylation is associated with Met, the interac-
tion of STAT3 andMet was investigated using an immunoprecip-
itation assay. ()-Antofine treatment for 24 hr led to significantly
decreased binding of STAT3 to Met (Figure 5B).
The nuclear translocation of STAT3 is dependent on active
Met trafficking to the perinuclear compartment. Moreover,
STAT3 nuclear accumulation plays a crucial role in HGF-depen-
dent wound healing (Kermorgant and Parker, 2008; Sano et al.,
1999). To investigate whether the effect of ()-antofine on the
downstream signaling of Met is associated with the regulation
of endosomal signaling, further experiments were carried out.
When STAT3 levels in the cytosol and nucleuswere examined af-
ter treatment with ()-antofine for 24 hr, it was found that the
expression of STAT3 in the nucleus decreased and that the
expression of STAT3 in the cytosol increased (Figure 5C). In
addition, incubation of Caki-1 cells with ()-antofine for 24 hr
blocked wound closure effectively in a concentration-dependent
manner in wound healing experiments (Figure 5D). Therefore,
these findings suggest that ()-antofine regulates the endosomal
signaling of Met and subsequently affects its downstream tar-
gets (Kermorgant and Parker, 2008).
We confirmed these findings using confocal microscopy (Fig-
ure 5E). With ()-antofine treatment, the localization of Met and
STAT3 in cytosolic fractions was time dependent. In addition,
Met and STAT3 always colocalized.
(–)-Antofine Inhibits In Vivo Tumor Growth by Regulating
Met Endosomal Signaling
A tumor xenograft model was used to examine the in vivo anti-
tumor activity of ()-antofine. Nude mice subcutaneously en-
grafted with Caki-1 cells were randomized to receive oral admin-
istration of either the vehicle (normal saline) or ()-antofine
(5 mg/kg body weight). At the termination of the experiment
(42 days after inoculation), tumor volumes of the control group
were approximately 850 mm3, whereas tumor volumes of the
()-antofine-treated group were inhibited by 59% (p < 0.001).
In fact, the difference in the tumor volumes was statistically sig-
nificant (p < 0.01) 13 days after ()-antofine treatment (Figure 6A).
Moreover, the change in body weight and overt toxicity were
negligible for ()-antofine treatment (data not shown). These
data confirmed that ()-antofine effectively inhibits the tumor
growth of renal cancer cells in vivo.
Biochemical analysis of tumor tissues were conducted to
verify the findings in vitro. The interaction of Met and STAT3
was investigated using an immunoprecipitation assay with pro-510 Chemistry & Biology 22, 504–515, April 23, 2015 ª2015 Elsevierteins extracted from frozen xenograft tumor tissue samples.
The binding of Met with STAT3 was markedly decreased by
()-antofine as judged by immunoprecipitation with Met anti-
body (Figure 6B). The nuclear translocation of STAT3 was
explored by nuclear and cytosolic fractionation. As shown in Fig-
ure 6C, ()-antofine suppressed the expression of STAT3 in the
nuclear fraction, whereas it increased the expression of STAT3 in
the cytosol. Furthermore, the expression levels of Met, phospho-
Met (Y1234/1235), STAT3, and phospho-STAT3 (Y705) were
examined using immunohistochemical analysis. ()-Antofine
suppressed the expression of Met and phospho-Met. Although
()-antofine did not affect the expression of STAT3, the expres-
sion of phospho-STAT3 by ()-antofine was strongly sup-
pressed (Figure 6D). Because the STAT3 nuclear accumulation
through Met activation correlates with a strong nuclear signal
for STAT3 phosphorylated on tyrosine 705, these results
confirmed the effects of ()-antofine on the regulation of the
Met endosomal signaling in vivo as well as in vitro.
DISCUSSION
In the present study, we demonstrated that the regulation of Met
signaling is a plausible molecular target to account for the anti-
cancer activity of ()-antofine, a representative phenanthroindo-
lizidine alkaloid. The antiproliferative activity of ()-antofine was
found to be dependent on the expression of Met or its ligand
HGF in various cancer cell lines. We also found that ()-antofine
suppressed the endosomal signaling of Met by enhancing Met
degradation as well as inhibiting Met endocytosis and recycling
in themetastatic Caki-1 human cancer cell line. Phenanthroindo-
lizidine alkaloids have received significant attention as candi-
dates for anticancer agents but the specific target is still un-
known. A variety of potential cellular activities have been
identified, including the suppression of DNA and protein synthe-
sis and the inhibition of NF-kB signaling, but Met endosomal
signaling, which we suggest as a novel target of ()-antofine, is
completely different from those previously described.
Recently, it has been revealed that RTK endosomal signaling
promotes signals and functions that play an important role in
oncogenesis (Gould and Lippincott-Schwartz, 2009). Clathrin-
mediated endocytosis of EGFR is required for controlling spe-
cific EGFR-dependent signaling pathways and the endosomes
containing nerve growth factor (NGF) activate Ras-MAPK
signaling pathways (Howe et al., 2001; Vieira et al., 1996). HIP1
and Rab25, endocytic proteins, are overexpressed in cancers,
and mutant p53 drives cell invasion and metastasis by inducing
EGFR recycling and constitutive activation of EGFR/integrin
signaling (Mosesson et al., 2008; Muller et al., 2009). The Met
signaling related to ERK1/2 and STAT3 occurs within endosomal
compartments, and STAT3-mediated wound healing is mainly
dependent on Met endosomal signaling (Kermorgant and
Parker, 2008; Kermorgant et al., 2004). When mutated, Met
was continuously retrieved by endocytosis, recycling, and
impaired degradation, processes that contribute to the mainte-
nance of the receptor on endosomes and hyperactivation of en-
dosomal signaling. Because there is evidence that endosomal
signaling and cancer development are directly related, hyperac-
tivated endosomal signaling might be a plausible basis for Met
TKI resistance.Ltd All rights reserved
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Figure 5. (–)-Antofine Suppresses STAT3 Activity by Regulating Met Endosomal Signaling
(A) Western blot analysis of Caki-1 cells. Cells were treated with the indicated concentrations of ()-antofine for 24 hr, and the expression of the indicated proteins
was determined using Western blot analysis.
(B) Immunoprecipitation of Caki-1 cells. Cells were treated with the indicated concentrations of ()-antofine for 24 hr. The total cell lysates were immunopre-
cipitated with STAT3 antibody and immunoblotted with the indicated antibodies.
(C) Isolation of cytosolic and nuclear extracts was performed using Caki-1 cells. Cells were treated with the indicated concentrations of ()-antofine for 24 hr, and
then the expression of STAT3 was analyzed using Western blot analysis. Poly (ADP-ribose) polymerase (PARP) was used as a nuclear fraction marker.
(D) Representative pictures of wound healing of Caki-1 cells. Cells were incubated with the indicated concentrations of ()-antofine for 24 hr. Magnification,
2003.
(E) Confocal microscopy analysis of Caki-1 cells. Cells were treated with 25 nM ()-antofine for the indicated times and stained with Met, STAT3, and DAPI. Scale
bars represent 40 mm.
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Figure 6. (–)-Antofine Inhibits Tumor
Growth by Regulating Met Endosomal
Signaling
(A) The antitumor activity of ()-antofine. Caki-1
cells (1 3 107 cells/mouse) were injected subcu-
taneously into the flanks of nude mice. Treatment
with the test compounds was initiated when tumor
volumes reached 100 mm3. ()-Antofine (5 mg/
kg body weight) was administered orally five times
per week in a volume of 200 ml. The control group
was treated with an equal volume of vehicle. Tu-
mor volumes were measured with a caliper every
2–3 days (*p < 0.05 was considered statistically
significant, ***p < 0.001). Data are represented as
means ± SD.
(B) Immunoprecipitation of Caki-1 xenograft tu-
mors. The tumor lysates were immunoprecipitated
with Met antibody and immunoblotted with the
indicated antibodies.
(C) Isolation of cytosolic and nuclear extracts was
performed with Caki-1 xenograft tumors. The
expression of STAT3 was analyzed using Western
blot analysis. Lamin B was used as a nuclear
fraction marker.
(D) Immunohistochemical analysis of Caki-1
xenograft tumors. Formalin fixed, paraffin-
embedded tumor sections were blocked and
probed with Met, phospho-Met, STAT3, and
phospho-STAT3 antibodies, which were detected
using the LSAB + System-HRP kit (Dako). Sec-
tions were counterstained with hematoxylin and
photographed with an inverted phase-contrast
microscope (original magnification, 1003).We found that Caki-1 cells, which have the V1238I missense
mutation in Met, are resistant to known Met TKIs, including ca-
bozantinib and BMS777607. We also found that, in Caki-1 cells,
Met endocytosis is enhanced and Met is constitutively shuttled
between endosomes and peripheral membranes without HGF
activation. Thus, Met-mediated signaling pathways are hyperac-
tivated and this might be a possible mechanism of resistance to
Met TKIs in Caki-1 cells. However, ()-antofine exhibited potent
antiproliferative activity against Caki-1 cells and this activity was
found to be dependent on the expression of Met or its ligand
HGF in various cancer cell lines. ()-Antofine suppresses the
expression of phospho-Met without directly inhibitingMet kinase
activity in Caki-1 cells. ()-Antofine enhances c-cbl-dependent
Met ubiquitination and subsequent proteasomal degradation.
Moreover, ()-antofine inhibited Met endocytosis and recycling
in the cell compartments. These results suggest that ()-antofine
inhibits Met activation through negative regulation of endosomal
signaling, a different mechanism of action than that of other con-
ventional Met TKIs. This event might lead to ()-antofine potently
suppressing the expression of phospho-Met even in the Caki-1
cell line.
STAT3 is known as one of the endosomal target molecules of
Met and thus plays a role in theMet-mediated signaling pathway.
TheMet endosomal signaling requires STAT3 nuclear accumula-
tion through the phosphorylation of tyrosine 705 of STAT3, and
the nuclear accumulation of STAT3 is indispensable for cell
migration (Kermorgant and Parker, 2008). ()-Antofine sup-
pressed the activation of STAT3 and the translocation of512 Chemistry & Biology 22, 504–515, April 23, 2015 ª2015 ElsevierSTAT3 into the nucleus, which leads to the inhibition of cancer
cellmigration. These resultswere further investigated in an in vivo
tumor xenograft model. Oral administration of ()-antofine
significantly inhibited tumor growth in nude mice implanted
with Caki-1 cells, and it suppressed Met-mediated STAT3 acti-
vation. These data confirmed that ()-antofine inhibitsMet endo-
somal signaling in the in vivo model.
In summary, we suggest for the first time that ()-antofine is a
negative regulator of Met endosomal signaling. Because Met
signaling mediates a wide variety of cellular processes, these
findings can be used to encompass known targets of ()-anto-
fine. As far as we know, there is no previous report of small mol-
ecules regulating Met endosomal signaling. Therefore, these
findings are meaningful not only because they reveal a novel
target of ()-antofine but also because targeting Met endosomal
signaling could provide a novel therapeutic approach toMet TKI-
resistant cancers. In addition, phenanthroindolizidine alkaloids,
exemplified by ()-antofine, might be applicable chemothera-
peutic agents for treating cancer cells characterized by Met
overexpression or Met mutational activation.
SIGNIFICANCE
Met RTK is aberrantly activated through overexpression
or mutation in a variety of cancers and considered to be
an attractive molecular target for cancer therapy. The
ligand HGF binding toMet triggers signaling pathways asso-
ciated with cell proliferation, migration, and invasion.Ltd All rights reserved
Met-mediated signalings are also activated independent of
ligands, especially by the activating mutations of Met.
Mutated Met enhances its endocytosis and subsequent
intracellular trafficking, eventually leading to the accumula-
tion of activated Met on endosomes. Therefore, although
small-molecule inhibitors of Met have exhibited a potent
antitumor activity, tumors harboring activating Met muta-
tions have been shown to be resistant to these Met TKIs.
In this study, we present Met endosomal signaling as a
novel target for a phenantroindolizidine alkaloid, (–)-anto-
fine. (–)-Antofine effectively inhibited the proliferation of
Met-mutated Caki-1 renal cancer cells, which were found
to be resistant to well-known Met TKIs. Unlike other Met
TKIs, (–)-antofine did not directly inhibit Met kinase activity,
but it increased Met proteasomal degradation and sup-
pressed the Met endosomal trafficking and recycling.
Thus, it subsequently suppressed the Met-mediated down-
stream signalings. (–)-Antofine also inhibited the nuclear
translocation of STAT3 by regulating Met endosomal
signaling. Oral administration of (–)-antofine inhibited tu-
mor growth in nude mice implanted with xenografts of
Caki-1 cells, and it suppressed STAT3 and Met signaling.
This is the first report to demonstrate the involvement of
Met endosomal signaling in the anticancer activity of phe-
nanthroindolizidine alkaloids in renal cancer cells with an
activating Met mutation.EXPERIMENTAL PROCEDURES
Reagents
DMEM, RPMI 1640 medium, TRI reagent, Lipofectamine RNAiMAX, CBL-
specific siRNA, negative control siRNA, Opti-MEM Reduced Serum Medium
were purchased from Invitrogen. Mouse anti-Ub, anti-LAMP1, anti-STAT3,
anti-phospho-STAT3, anti-phospho-ERK1/2, anti-b-actin, rabbit anti-Met,
anti-cbl, anti-Grb2, anti-RAC1, anti-ERK1/2, and goat anti-Met were pur-
chased from Santa Cruz Biotechnology. Rabbit anti-phospho-Met (Y1003),
anti-phospho-Met (Y1234/1235), anti-Src, and anti-phospho-Src were pur-
chased from Cell signaling Technology. Gene-specific primers for real-time
PCR were synthesized from Bioneer. The Reverse Transcription Kit was pur-
chased from Promega. Protein G sepharose beads were purchased from GE
Healthcare.
Compounds
()-Antofine (purity >98%, high-performance liquid chromatography) was syn-
thesized as previously described (Kim et al., 2003, 2004). PHA665752, cabo-
zantinib (Exelixis), and BMS777607 were purchased from Selleckchem. The
MG132 and cycloheximide were purchased from A.G. Scientific.
Cell Culture
The human renal cancer (Caki-1), lung cancer (A549), glioblastoma (U87MG),
breast cancer (MDA-MB-231), prostate cancer (PC-3), and colon cancer
(SW480) cell lines were obtained from the Korean Cell Line Bank. Every
6 months, all cell lines were tested for mycoplasma contamination by using
the mycoplasma PCR detection kit (Intron biotechnology). Cells were grown
in medium (DMEM for Caki-1, U87MG, and MDA-MB-231 cells, and RPMI
1640 medium for A549 and PC-3 cells) supplemented with 10% fetal bovine
serum (FBS) and antibiotics-antimycotics (100 units/ml penicillin G sodium,
100 mg/ml streptomycin, and 250 ng/ml amphotericin B [PSF]). SW480 cells
were grown in RPMI 1640 medium containing 25 mM HEPES, 10% FBS,
and PSF.
All cells were incubated at 37C in a humidified atmosphere containing 5%
CO2 and subcultured twice a week. Cells passaged more than three times
were used for the experiments.Chemistry & Biology 22,The Phospho-RTK Array
Phosphorylated RTKs were measured with the Human Phospho-RTK Array Kit
(ARY001B) from R&D Systems according to the manufacturer’s instructions.
RNA Extraction and Real-Time PCR
RNA extraction and real-time PCR were carried out as described previously
(Kim et al., 2012). The following sequences were used: MET F50-AATAG
AAAACTGACAATGTTGAGAGG-30; MET R50-TGAAATTCATCCAACCAAATC
TT-30; HGF F50-CCATTCTCATTTTATGTTGCTCA-30; HGF R50-GATTGGATC
AGGACCATGTGA-30; ATCB F50-AGCACAATGAAGATCAAGAT-30; ATCB
R50-TGTAACGCAACTAAGTCATA-30.
Western Blot Analysis
Western blot analysis was carried out as described previously (Kwon et al.,
2013).
Cell Proliferation Assay
The cell proliferation assay was carried out as described previously (Kwon
et al., 2013).
Met Kinase Enzyme Assay
Met kinase enzyme activity was measured with the MET Kinase Enzyme Sys-
tem (V9571) from Promega according to the manufacturer’s instructions.
Immunoprecipitation
Cells were lysed in IP lysis buffer (50mMTris-HCl [pH 7.4], 150mMNaCl, 1mM
EDTA, 0.5% NP-40) for in vitro experiments and in Complete Lysis Buffer
(Active Motif) for in vivo experiments. Protein concentrations were determined
using the Bradford protein assay. Equal amounts of protein were incubated
with the indicated antibodies and Protein G sepharose beads overnight at
4C. Beads were washed with IP lysis buffer and the bound proteins were
eluted with 23 Laemmli buffer.
RNAi
RNAi of the CBL gene was performed using a set of three stealth siRNAs
(HSS101416, HSS101417, and HSS101418) purchased from Invitrogen. For
transfection, reverse transfection was conducted using Lipofectamine
RNAiMAX (Invitrogen) according to the manufacturer’s recommendations.
Transfectants were treated with the compounds after 24 hr of transfection.
Immunocytochemistry
Cells were grown on coverglass-bottom dishes coated with 0.2%gelatin. After
treatment, the cells were fixed with 4% paraformaldehyde for 15 min and the
fixed cells were permeabilized with 0.1% Triton X-100 for 5 min. After being
blockedwith 1%BSA for 30min at room temperature, the cells were incubated
with primary antibody at 4C. Following overnight incubation, the cells were
incubated with fluorescence-conjugated secondary antibody for 2 hr at
room temperature. DAPI (0.5 mg/ml) was used to counterstain the nuclei.
The images were acquired using a Zeiss ApoTome microscope (Carl Zeiss).
Biotinylation Degradation Assay
Biotinylation degradation assays were performed as described previously with
a slight modification (Joffre et al., 2011). Briefly, cell surface proteins were
covalently labeled using amembrane-impermeant biotinylation reagent (N-hy-
droxysulfosuccinimide (sulfo-NHS)-SS-biotin, Pierce). Cells were washed in
PBS, incubated at 4C with 0.2 mg/ml sulfo-NHS-SS-biotin in PBS for
30 min and then incubated in culture medium with or without ()-antofine
for 4 hr at 37C to allow protein trafficking and degradation. After incubation
for the indicated time, the cells were washed with cold PBS and lysed. The ly-
sates were passed five times through a 26.5-gauge needle and clarified by
centrifugation (17,000 3 g for 10 min); equal amounts of the proteins were
mixed with streptavidin-agarose beads and agitated at 4C for 2 hr. The beads
were collected by centrifugation (7,000 3 g), washed in lysis buffer, and the
proteins were eluted by heating at 95C with 23 Laemmli buffer.
Biotinylation Internalization and Recycling Assay
Biotinylation internalization and recycling assays were also performed as
described previously with a slight modification (Joffre et al., 2011). Briefly,504–515, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 513
cell surface proteins were labeled with 0.2 mg/ml sulfo-NHS-SS-biotin in PBS
for 30 min on ice. Labeled cells were washed with cold PBS and incubated at
37C for 1 hr to allow internalization in culture medium with or without
()-antofine. After incubation for the indicated time, the medium was removed
and the cells were washed with cold PBS. Biotin was removed from the pro-
teins remaining at the cell surface by reduction with 180 mM of the mem-
brane-impermeant reducing agent MesNa (sodium 2-mercaptoethanesulfo-
nate, Sigma) in 50 mM Tris and 100 mM NaCl at pH 8.6. Cells were
incubated for 15 min on a rocker platform. The MesNa was quenched by the
addition of 180 mM iodoacetamide (Sigma) for 10 min on a rocker platform.
To measure internalized Met, the assay was then terminated and the cells
were lysed. Lysates were analyzed as in the biotinylation degradation assay.
To measure the proportion of the internalized Met that recycles back to the
cell surface, the internalized fraction was chased from the cells by returning
them to 37C for 1 hr. Cells were then returned to ice, and biotin was removed
from the recycled proteins by a second reduction with MesNa. Unreacted
MesNa was quenched with iodoacetamide, and the cells were lysed and pro-
cessed as for measurements of receptor internalization.
Isolation of Cytosolic and Nuclear Extracts
Cytosolic and nuclear extracts were isolated with the Nuclear extract Kit
(40410) from Active Motif according to the manufacturer’s instructions.
Wound Healing Assay
Caki-1 cells were seeded in six-well plates at a density of 13 105 cells/ml and
incubated for 48 hr until they reached 80%–90% confluence. A confluent
monolayer of Caki-1 cells was artificially wounded with a micropipette tip,
and the detached cells were washed with PBS and treated with ()-antofine
in growing medium for 24 hr. Images of the wounds were photographed at
0 and 24 hr under an inverted microscope (CKX41, Olympus).
In Vivo Tumor Xenograft Model
All animal use and care followed the guidelines approved by the Seoul National
University Institutional Animal Care and Use Committee (IACUC permission
number SNU-121114-1-1). The 4-week-old female athymic mice (BALB/c-nu)
were purchased fromCentral Laboratory Animal. A Caki-1 cell suspension (13
107 cells in 200 ml of medium) was injected subcutaneously into the right flank
of each mouse on day 0. The mice were treated when their tumor volume
reached 95–100 mm3. Based on the lethality and body weight loss exhibited
by the nude mice, they were randomized into vehicle control and treatment
groups of six animals per group. ()-Antofine (5 mg/kg body weight) was dis-
solved in 200 ml of vehicle solution (0.5% Tween 80 in normal saline) and
administered orally five times a week. The control group was treated with an
equal volume of vehicle. The tumor volume was monitored three times per
week for 42 days using calipers and estimated using the following formula: tu-
mor volume (mm3) = (width) 3 (length) 3 (height) 3 p/6. The body weight of
each mouse was also monitored for toxicity.
Immunohistochemistry of Tumors
The immunohistochemistry of the tumors was carried out as described previ-
ously with the indicated antibodies (Kwon et al., 2013).
Ex Vivo Biochemical Analysis of Tumors
A portion of the frozen tumor excised from each of the nude mice was thawed
on ice and homogenized in Complete Lysis Buffer (Active Motif) using a hand-
held homogenizer. The protein concentrations of the tumor lysates were deter-
mined and aliquots were stored at 80C.
Statistical Analysis
Statistical significance (p < 0.05) was assessed using Student’s t test or one-
way ANOVA coupled with Dunnett’s t test.
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